Drug profile · INN
silodosin
UROREC
silodosin (UROREC) is a alpha-1a adrenergic receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — silodosin
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
silodosin (UROREC) is a alpha-1a adrenergic receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Alpha-1a adrenergic receptor antagonist
Primary target: Alpha-1A adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is silodosin?
silodosin (UROREC) is a alpha-1a adrenergic receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for silodosin?
UROREC is a marketed brand name for silodosin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of silodosin?
silodosin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.